Inflammation: More Than Skin Deep in Psoriasis

CMEO Medical Meeting

Symposium Date/Time: Wednesday, November 16, 2016
5:15 PM – 6:45 PM
New York Academy of Medicine, New York, NY

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, November 16, 2017

Faculty

 

James G. Krueger, MD, PhD James G. Krueger, MD, PhD
D. Martin Carter Professor in Clinical Investigation
Head of Laboratory for Investigative Dermatology
Co-director, Center for Clinical and Translational Science
The Rockefeller University Hospital
New York, NY

 

Joel M. Gelfand, MD, MSCE Joel M. Gelfand, MD, MSCE
Professor of Dermatology
Professor of Epidemiology
Vice Chair of Clinical Research and Medical Director
Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

 

Iain B. McInnes, FRCP, PhD, FRSE Iain B. McInnes, FRCP, PhD, FRSE
Muirhead Chair of Medicine
Director, Institute of Infection, Immunity and Inflammation
Professor of Experimental Medicine
Director of Research Institute
(Immunology)
College of Medical, Veterninary and Life Sciences
University of Glasgow
Glasgow, Scotland
United Kingdom

 

Statement of Need

Individuals with psoriasis are at significant risk for psoriatic arthritis (PsA) and cardiovascular disease (CVD). Dermatologists treat the majority of patients with psoriasis and have an important role in screening for these disorders and effectively treating psoriasis according to the underlying inflammation.

However, gaps have been identified related to recognition of common pathogenic links between psoriasis and PsA, the awareness of the role of inflammatory cytokines and cellular mediators in the pathogenesis of psoriasis and CVD, and how treatment selection is impacted by the inflammatory mechanism of psoriasis.

This 90-minute symposium features expert faculty presenting the latest evidence and highlighting the mechanisms that link inflammatory disease to adverse cardiovascular outcomes. Faculty will explore current treatment paradigms for moderate to severe psoriasis and psoriatic arthritis and translate the evidence through patient vignettes.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the common pathogenic links between psoriasis and PsA to improve assessment and diagnosis in practice.
  • Illustrate the role of inflammatory cytokines and cellular mediators in the pathogenesis of psoriasis and CVD.
  • Integrate the role of treatment targets/pathways of new agents into treatment decisions for patients with psoriasis and PsA.

The following learning objectives pertain only to those requesting CNE credit:

  • Identify ways to integrate the role of treatment targets/pathways of new agents into treatment decisions for patients with psoriasis and PsA.

Financial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Target Audience

Dermatologists, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare providers with an interest in psoriasis.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)

Universal Activity Number: 0376-0000-16-029-L01-P

Type: knowledge-based

Successful completion of this CE activity includes participating in the live activity, reviewing the course materials, within 30 days of completion of the activity, and completing your activity evaluation and post-test online (75% pass rate required). You may print your certificate or statement of credit immediately. Please visit www.CMEOutfitters.com/20162(requires free account activation).

Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Krueger has disclosed that he has received research and grant support from Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Dermira, Inc.; Innovaderm Research Inc.; Janssen Pharmaceuticals, Inc.; Kadmon Corporation, LLC; Kyowa Hakko Kirin Co., Ltd.; LEO Pharma Inc.; Novartis; PAREXEL International Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Vitae Pharmaceuticals, Inc. He serves as a consultant for AbbVie Inc.; Baxter; Biogen Idec; Boehringer Ingelheim; Bristol-Myers Squibb Company; Dermira, Inc.; Janssen Pharmaceuticals, Inc.; Kadman Corporation, LLC; Kineta, Inc.; Eli Lilly and Company, Merck & Co.. Inc.; Novartis; Pfizer Inc.; sanofi-aventis U.S. LLC; EMD Serono, Inc.; and XenoPort, Inc.

Dr. Gelfand has disclosed that he has received research and grant support from AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Janssen Biologics, Inc. (formerly Centocor Biotech, Inc.); Novartis Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc; and Sanofi. He serves as a consultant for AbbVie Inc.; Amgen Inc.; AstraZeneca; Celgene Corporation; Coherus Biosciences; Eli Lilly and Company; Janssen Biologics, Inc. (formerly Centocor Biotech, Inc.); Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;Pfizer Inc.; Sanofi; and Valeant.

Dr. McInnes has disclosed that he has received research and grant support from Arthritis Research UK (ARUK) Centre of Excellence; Celgene Corporation; and UCB, Inc.. He serves as a consultant for AbbVie Inc.; AstraZeneca; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis; Pfizer, Inc.; and UCB, Inc.

Jeffrey Helfand, DO, MS (peer reviewer) has nothing to disclose.

Kimberley Murray, RN, MS (peer reviewer) has nothing to disclose.

Sharon Tordoff, CHCP (planning committee) has nothing to disclose.

Jan Perez, CHCP (planning committee) has nothing to disclose.

Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.

CME Outfitters, LLC, the faculty, and Lilly do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

Activity Content

Presentations Status